Diko : en:injection, human fibrinogen concentrate, 1 mg administered

en:injection, human fibrinogen concentrate, 1 mg administered

Catégories

Nom

Informations lexicales

Langue:anglais

Informations sémantiques

source:wiki

Liens externes

›

umls:C3496178

Associations d'idées

[F]

›

50+

en:complete gene sequence analysis for hemochromatosis genetic testing

•

en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incisio

•

en:automated eeg monitoring

•

en:miscellaneous drugs and solutions

•

en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period

•

en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer

•

en:anticoagulation was not ordered, reason not given

•

en:aneurysm minor diameter >6cm for men

•

en:5% dextrose in lactated ringers infusion, up to 1000 cc

•

en:5% dextrose/water (500 ml = 1 unit) administered

•

en:aneurysm minor diameter <= 5.5 cm for women

•

en:assessment of depression severity not documented, reason not given

•

en:clinician documented that patient was not an eligible candidate for autogenous av fistula

•

en:complete gene sequence analysis; msh2 gene

•

en:compounded drug, not otherwise classified

•

en:counseling for diet and physical activity performed

•

en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

•

en:aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)

•

en:administration of factor ix, complex, per i.u.

•

en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:aneurysm minor diameter <= 5.5 cm

•

en:anoscopy; with directed submucosal injection(s), any substance

•

en:antiplatelet medication contraindicated

•

en:cd4+ cell count or cd4+ cell percentage results documented

•

en:abdominal aortic aneurysm is not infarenal

•

en:prescription(s) generated and transmitted via a qualified erx system

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient

•

en:injection, sculptra, 0.1 ml

•

en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:patients with a positive hepatitis c antibody test

•

en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea

•

en:score on the swallowing functional communication measure at discharge was higher than at admission

•

en:serum creatinine test not performed, reason not given

•

en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given

•

en:5% dextrose/normal saline (500 ml = 1 unit) administered

•

en:injection, dexamethasone, intravitreal implant, 0.1 mg

•

en:lipid profile not performed, reason not given

•

en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries

•

en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain

•

en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf

•

en:clinician documented that patient with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic function was not an eligible candidate for angiotensin converting enzyme (ace) inhibi

•

en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given

•

en:autogenous av fistula received

•

en:assessed level of activity and symptoms

▶

‹

50+

en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month

•

en:patch closure used for patient undergoing conventional cea

•

en:score on the motor speech functional communication measure at discharge was higher than at admission

•

en:injection, von willebrand factor complex (humate-p), per iu vwf:rco

•

en:patients with a positive hepatitis c antibody test

•

en:most recent blood pressure under control

•

en:infusion, normal saline solution, sterile (500 ml=1 unit)

•

en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:injection, brentuximab vedotin, 1 mg

•

en:injection, morphine sulfate, 100mg

•

en:ganciclovir, 4.5 mg, long-acting implant

•

en:etonogestrel (contraceptive) implant system, including implant and supplies

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase

•

en:grafix prime, per square centimeter

•

en:complete gene sequence analysis; mlh1 gene

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery

•

en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason

•

en:injection, factor ix, fc fusion protein (recombinant), per iu

•

en:methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram

•

en:unlisted procedure, intestine

•

en:score on the spoken language expression functional communication measure at discharge was higher than at admission

•

en:suicide risk not assessed at the initial evaluation, reason not given

•

en:serum creatinine test not performed, reason not given

•

en:score on the reading functional communication measure at discharge was higher than at admission

•

en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered

•

en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)

•

en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed

•

en:electronic wrist rotator, otto bock or equal

•

en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge

•

en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel

•

en:injection, testosterone enanthate, up to 200 mg administered

•

en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient

•

en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)

•

en:most recent ldl-c not under control, results documented and reviewed

•

en:counseling for diet and physical activity not performed, reason not given

•

en:urine protein test was not performed, reason not given

•

en:injection, human fibrinogen concentrate, 100 mg

•

en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents

•

en:score on the attention functional communication measure at discharge was higher than at admission

•

en:ldl value >= 100

•

en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg

•

en:hyaluronan or derivative, gel-syn, for intra-articular injection, 0.1 mg

•

en:antithrombin iii (human), per i.u. administered

•

en:factor ix (antihemophilic factor, recombinant) per i.u.

•

en:patient not treated for memory disorder

•

en:score on the swallowing functional communication measure at discharge was higher than at admission

•

en:injection, testosterone enanthate, up to 100 mg administered

•

en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

▶

• Mathieu Lafourcade • LIRMM (données libres en Creative Commons) •

• This page link : https://www.jeuxdemots.org/diko.php?gotermid=8088049 • caches: c1=12 c2=201 c3=626

+/-

♥

po

la

ti

le

as

ku

co

lo

to

ta

ta

xe

po

li

?!

!?

[Vider le cache]

A propos

Champs masqués